Companies

RVMD · Biotech

Revolution Medicines, Inc.

SEC company filings

Reported cash

USD 615,908,000

Sep 30, 2026

SEC filing

Cash and cash equivalents · Restricted cash and marketable securities excluded

Cash verified Nov 16, 2026

Price chart

What changed?

Upcoming catalysts

Next verified event · Clinical readout window

Colorectal cancer clinical data update · H1 2027

Timing updated · History

Postponed to a later window

Previous: Q4 2026 · quarter precision

Announced Aug 5, 2026

Previous official source

The company continues to evaluate multiple combination approaches in CRC, including RAS(ON) inhibitor doublets and combinations with standard of care and other investigational therapies. The company expects to provide updated clinical data and additional visibility into its CRC development strategy during the fourth quarter of 2026.

Current: H1 2027 · half precision

Announced Nov 4, 2026

Current official source

Under the companies’ existing agreement, BeOne Medicines is funding and conducting the trial on Revolution Medicines’ behalf. Revolution Medicines expects to provide a clinical data update from its earlier phase CRC studies along with the RASonate 312 trial design in the first half of 2027.

Announced Nov 4, 2026 · Announced window

Official announcement
Source wording

Under the companies’ existing agreement, BeOne Medicines is funding and conducting the trial on Revolution Medicines’ behalf. Revolution Medicines expects to provide a clinical data update from its earlier phase CRC studies along with the RASonate 312 trial design in the first half of 2027.

Clinical readout window

RASolve 301 · 2027

previously treated RAS mutant NSCLC

Phase 3

NCT06881784

Announced Nov 4, 2026 · Announced window

Official announcement
Source wording

Development of daraxonrasib in previously treated RAS mutant NSCLC continues to advance. Global enrollment in RASolve 301, the Phase 3 trial evaluating daraxonrasib in this setting, is winding down with all sites expected to close enrollment by the end of November 2026, supporting an anticipated initial readout in 2027. Previously reported Phase 1/2 clinical data evaluating daraxonrasib in RAS mutant NSCLC were publi

Clinical readout window

RMC-5127 · 2027

Announced Nov 4, 2026 · Announced window

Official announcement
Source wording

The company continues enrollment in the ongoing first-in-human trial evaluating RMC-5127, its oral RAS(ON) G12V-selective, noncovalent inhibitor, and is nearing selection of a candidate recommended Phase 2 dose. The company expects to report initial clinical monotherapy data in 2027.

Drug pipeline

37 programs · 19 verified studies

5-fluorouracil

Phase

Phase3

Study status

Active not recruiting
View details

Revolution Medicines, Inc.

IndicationPancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma

Estimated study completion2027-12

5-fluorouracil

Phase

Phase3

Study status

Recruiting
View details

Revolution Medicines, Inc.

IndicationPancreatic Cancer; Pancreatic Cancer Metastatic; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenocarcinoma; Pancreatic Adenosquamous Carcinoma

Estimated study completion2030-04-22

bevacizumab

Phase

Phase1 / Phase2

Study status

Recruiting
View details

Revolution Medicines, Inc.

IndicationColorectal Cancer; CRC; Pancreatic Ductal Adenocarcinoma; PDAC; Gastrointestinal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma

Estimated study completion2030-03-30

Carboplatin

Phase

Phase1 / Phase2

Study status

Recruiting
View details

Revolution Medicines, Inc.

IndicationNon-Small Cell Lung Cancer, NSCLC; KRAS, NRAS, HRAS-mutated NSCLC; KRAS G12C-mutated Solid Tumors, Lung Cancer; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer; RAS G12D-mutated NSCLC

Estimated study completion2028-12

Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only)

Phase

Phase1 / Phase2

Study status

Recruiting
View details

Revolution Medicines, Inc.

IndicationAdvanced Solid Tumors; Metastatic Solid Tumors; Non-small Cell Lung Cancer (NSCLC); NSCLC; Colorectal Cancer (CRC); CRC

Estimated study completion2029-05

Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)

Phase

Phase1 / Phase2

Study status

Recruiting
View details

Revolution Medicines, Inc.

IndicationAdvanced Solid Tumors; Metastatic Solid Tumors; Non-small Cell Lung Cancer (NSCLC); NSCLC; Colorectal Cancer (CRC); CRC

Estimated study completion2029-05

cetuximab

Phase

Phase1 / Phase2

Study status

Recruiting
View details

Revolution Medicines, Inc.

IndicationColorectal Cancer; CRC; Pancreatic Ductal Adenocarcinoma; PDAC; Gastrointestinal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma

Estimated study completion2030-03-30

cetuximab

Phase

Phase1

Study status

Recruiting
View details

Revolution Medicines, Inc.

IndicationNon-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Adenocarcinoma; Pancreatic Ductal Adenocarcinoma (PDAC); PDAC; CRC; NSCLC; Pancreatic Cancer; Lung Cancer (NSCLC); Advanced Solid Tumors

Estimated study completion2028-10

cetuximab (Cohort C2 Only)

Phase

Phase1 / Phase2

Study status

Recruiting
View details

Revolution Medicines, Inc.

IndicationAdvanced Solid Tumors; Metastatic Solid Tumors; Non-small Cell Lung Cancer (NSCLC); NSCLC; Colorectal Cancer (CRC); CRC

Estimated study completion2029-05

Cisplatin

Phase

Phase1 / Phase2

Study status

Recruiting
View details

Revolution Medicines, Inc.

IndicationNon-Small Cell Lung Cancer, NSCLC; KRAS, NRAS, HRAS-mutated NSCLC; KRAS G12C-mutated Solid Tumors, Lung Cancer; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer; RAS G12D-mutated NSCLC

Estimated study completion2028-12

1 / 7

6 unverified sponsor matches remain unlinked.

Verified timeline

1 records